## Jean-Pierre Gangneux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4777133/publications.pdf

Version: 2024-02-01

110 5,212 37 68 papers citations h-index g-index

118 118 118 6068
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. Clinical Microbiology and Infection, 2022, 28, 580-587.	6.0	133
2	Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis (CAPA): a Multicenter Study. Journal of Clinical Microbiology, 2022, 60, JCM0168921.	3.9	23
3	Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respiratory Medicine,the, 2022, 10, 180-190.	10.7	161
4	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe, The, 2022, 3, e464-e470.	<b>7.</b> 3	35
5	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	7.3	255
6	Migrants et maladies parasitaires d'importation. Revue Francophone Des Laboratoires, 2022, 2022, 79-80.	0.0	0
7	Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply. Lancet Respiratory Medicine,the, 2022, , .	10.7	0
8	Quantitative Health Risk Assessment of the Chronic Inhalation of Chemical Compounds in Healthcare and Elderly Care Facilities. Toxics, 2022, 10, 141.	3.7	6
9	Efficient and Quality-Optimized Metagenomic Pipeline Designed for Taxonomic Classification in Routine Microbiological Clinical Tests. Microorganisms, 2022, 10, 711.	3.6	9
10	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. European Respiratory Journal, 2022, 59, 2102950.	6.7	9
11	Indoor Carbon Dioxide, Fine Particulate Matter and Total Volatile Organic Compounds in Private Healthcare and Elderly Care Facilities. Toxics, 2022, 10, 136.	3.7	13
12	Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study. BMC Infectious Diseases, 2022, 22, 352.	2.9	0
13	Cryptococcal Meningitis in Kidney Transplant Recipients: A Two-Decade Cohort Study in France. Pathogens, 2022, 11, 699.	2.8	6
14	Evaluation of Commercial Concentration Methods for Microscopic Diagnosis of Protozoa and Helminths in Human Stool Samples in a Non-Endemic Area. Microorganisms, 2022, 10, 1237.	3.6	0
15	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	9.1	586
16	Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of Experts. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 35-45.	0.4	4
17	COVID-19–Associated Pulmonary Aspergillosis, March–August 2020. Emerging Infectious Diseases, 2021, 27, 1077-1086.	4.3	175
18	Evaluation of the Allplexâ,,¢ GI-Helminth(I) Assay, the first marketed multiplex PCR for helminth diagnosis. Parasite, 2021, 28, 33.	2.0	11

#	Article	IF	Citations
19	Fungal infections in transplant recipients: pros and cons of immunosuppressive and antimicrobial treatment. Lancet Microbe, The, 2021, 2, e6-e8.	7.3	3
20	The Extent of Aspergillosis in Critically III Patients With Severe Influenza Pneumonia: A Multicenter Cohort Study. Critical Care Medicine, 2021, 49, 934-942.	0.9	29
21	Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis. Critical Care, 2021, 25, 152.	5.8	9
22	Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?. Journal of Fungi (Basel, Switzerland), 2021, 7, 388.	3.5	26
23	Proteomic Analysis of Humoral Immune Components in Bronchoalveolar Lavage of Patients Infected or Colonized by Aspergillus fumigatus. Frontiers in Immunology, 2021, 12, 677798.	4.8	4
24	The challenge of access to refined fungal diagnosis: An investment case for low- and middle-income countries. Journal De Mycologie Medicale, 2021, 31, 101140.	1.5	5
25	A review of significance of <i>Aspergillus</i> detection in airways of ICU COVID‶9 patients. Mycoses, 2021, 64, 980-988.	4.0	20
26	ECMM/ISHAM recommendations for clinical management of COVIDâ€19 associated mucormycosis in low― and middleâ€income countries. Mycoses, 2021, 64, 1028-1037.	4.0	137
27	COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave. Microbiology Spectrum, 2021, 9, e0113821.	3.0	32
28	Indoor Air Quality in Healthcare and Care Facilities: Chemical Pollutants and Microbiological Contaminants. Atmosphere, 2021, 12, 1337.	2.3	10
29	Chromoblastomycosis Due to a Never-before-Seen Dematiaceous Fungus in a Kidney Transplant Patient. Microorganisms, 2021, 9, 2139.	3.6	2
30	Des cerfs-volants dans les selles. Revue Francophone Des Laboratoires, 2021, 2021, 77-79.	0.0	0
31	Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD® Strongyloides ratti ELISA assay. Parasite, 2021, 28, 79.	2.0	5
32	Asthma and Indoor Environment: Usefulness of a Global Allergen Avoidance Method on Asthma Control and Exposure to Molds. Mycopathologia, 2020, 185, 367-371.	3.1	3
33	Bridging the knowledge gap on mycoses in Africa: Setting up a Panâ€African Mycology Working Group. Mycoses, 2020, 63, 244-249.	4.0	18
34	Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. Journal of Fungi (Basel, Switzerland), 2020, 6, 216.	3.5	21
35	Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience. Journal of Fungi (Basel, Switzerland), 2020, 6, 105.	3.5	50
36	Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive) Tj ETQq0 0 0 rg	BT /Overlo 3.5	ock 10 Tf 50 61 3

#	Article	IF	CITATIONS
37	Metagenomic Characterization of Indoor Dust Bacterial and Fungal Microbiota in Homes of Asthma and Non-asthma Patients Using Next Generation Sequencing. Frontiers in Microbiology, 2020, 11, 1671.	3.5	23
38	Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe, The, 2020, 1, e53-e55.	7.3	158
39	Evaluation of MucorGenius $\hat{A}^{\otimes}$ mucorales PCR assay for the diagnosis of pulmonary mucormycosis. Journal of Infection, 2020, 81, 311-317.	3.3	57
40	Differential Interactions of Serum and Bronchoalveolar Lavage Fluid Complement Proteins with Conidia of Airborne Fungal Pathogen Aspergillus fumigatus. Infection and Immunity, 2020, 88, .	2.2	9
41	European confederation of medical mycology expert consult—An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
42	IL-33/ST2 axis is involved in disease progression in the spleen during Leishmania donovani infection. Parasites and Vectors, 2020, 13, 320.	2.5	5
43	Invasive fungal diseases during COVID-19: We should be prepared. Journal De Mycologie Medicale, 2020, 30, 100971.	1.5	250
44	Evaluation of the AllplexTM Gastrointestinal Panelâ€"Parasite Assay for Protozoa Detection in Stool Samples: A Retrospective and Prospective Study. Microorganisms, 2020, 8, 569.	3.6	20
45	ECMM <i>Candi</i> Regâ€"A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
46	A European ECMMâ€ESCMID survey on goals and practices for mycobiota characterisation using nextâ€generation sequencing. Mycoses, 2019, 62, 1096-1099.	4.0	8
47	Real-time PCR for diagnosis of imported schistosomiasis. PLoS Neglected Tropical Diseases, 2019, 13, e0007711.	3.0	40
48	Dibothriocephalus nihonkaiensis: an emerging concern in western countries?. Expert Review of Anti-Infective Therapy, 2019, 17, 677-679.	4.4	5
49	Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1581-1584.	2.9	28
50	Les helminthoses à tropisme hépatique. Revue Francophone Des Laboratoires, 2019, 2019, 73-80.	0.0	1
51	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection. Journal of Fungi (Basel, Switzerland), 2019, 5, 116.	<b>3.</b> 5	12
52	Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure. Travel Medicine and Infectious Disease, 2018, 24, 31-36.	3.0	26
53	Improving the diagnosis of invasive aspergillosis by the detection of Aspergillus in broncho-alveolar lavage fluid: Comparison of non-culture-based assays. Journal of Infection, 2018, 76, 196-205.	3.3	38
54	Pneumocystis jirovecii and Cystic Fibrosis in Brittany, France. Mycopathologia, 2018, 183, 81-87.	3.1	12

#	Article	IF	CITATIONS
55	Eighty Years of Mycopathologia: A Retrospective Analysis of Progress Made in Understanding Human and Animal Fungal Pathogens. Mycopathologia, 2018, 183, 859-877.	3.1	21
56	Comparison of three commercial multiplex PCR assays for the diagnosis of intestinal protozoa. Parasite, 2018, 25, 48.	2.0	28
57	Performance of Molecular Approaches for Aspergillus Detection and Azole Resistance Surveillance in Cystic Fibrosis. Frontiers in Microbiology, 2018, 9, 531.	3 <b>.</b> 5	26
58	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	4.0	52
59	Indoor air quality in two French hospitals: Measurement of chemical and microbiological contaminants. Science of the Total Environment, 2018, 642, 168-179.	8.0	77
60	Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study. Infectious Diseases and Therapy, 2018, 7, 309-325.	4.0	5
61	Soluble CD14 acts as a DAMP in human macrophages: origin and involvement in inflammatory cytokine/chemokine production. FASEB Journal, 2017, 31, 1891-1902.	0.5	42
62	Epidemiology of <i>Trichophyton verrucosum &lt; /i&gt;infection in Rennes University Hospital, France: A 12-year retrospective study. Medical Mycology, 2017, 55, myw142.</i>	0.7	34
63	Home Environmental Interventions for the Prevention or Control of Allergic and Respiratory Diseases: What Really Works. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 66-79.	3.8	39
64	Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. Journal of Antimicrobial Chemotherapy, 2017, 72, 181-189.	3.0	46
65	Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea. PLoS Neglected Tropical Diseases, 2017, 11, e0006094.	3.0	50
66	Environmental Fungal Risk in Health Facilities. , 2017, , 303-319.		2
67	Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, <i>Candida</i> Colonization, and Multiple Organ Failure. JAMA - Journal of the American Medical Association, 2016, 316, 1555.	7.4	152
68	An estimation of burden of serious fungal infections in France. Journal De Mycologie Medicale, 2016, 26, 385-390.	1.5	71
69	Contribution of molecular tools for the diagnosis and epidemiology of fungal chronic rhinosinusitis. Medical Mycology, 2016, 54, 794-800.	0.7	20
70	Crucial and Diverse Role of the Interleukin-33/ST2 Axis in Infectious Diseases. Infection and Immunity, 2015, 83, 1738-1748.	2.2	75
71	A 10-Year Retrospective Comparison of Two Target Sequences, REP-529 and B1, for Toxoplasma gondii Detection by Quantitative PCR. Journal of Clinical Microbiology, 2015, 53, 1294-1300.	3.9	60
72	Leishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugates. Organic and Biomolecular Chemistry, 2015, 13, 8393-8404.	2.8	39

#	Article	IF	Citations
73	High negative predictive value diagnostic strategies for the reevaluation of early antifungal treatment: A multicenter prospective trial in patients at risk for invasive fungal infections. Journal of Infection, 2015, 71, 258-265.	3.3	14
74	Identification, biochemical characterization, and in-vivo expression of the intracellular invertase BfrA from the pathogenic parasite Leishmania major. Carbohydrate Research, 2015, 415, 31-38.	2.3	7
75	Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Medicine, 2015, 41, 1931-1940.	8.2	53
76	Prevalence of and risk factors for acute mountain sickness among a cohort of high-altitude travellers who received pre-travel counselling. Travel Medicine and Infectious Disease, 2014, 12, 534-540.	3.0	18
77	Diagnosis of Pneumocystis jirovecii Pneumonia in Immunocompromised Patients by Real-Time PCR: a 4-Year Prospective Study. Journal of Clinical Microbiology, 2014, 52, 3370-3376.	3.9	96
78	Indoor fungal contamination: Health risks and measurement methods in hospitals, homes and workplaces. Critical Reviews in Microbiology, 2014, 40, 248-260.	6.1	85
79	Comparative Evaluation of Three Impactor Samplers for Measuring Airborne Bacteria and Fungi Concentrations. Journal of Occupational and Environmental Hygiene, 2013, 10, 455-459.	1.0	6
80	Possible application of the Environmental Relative Moldiness Index in France: A pilot study in Brittany. International Journal of Hygiene and Environmental Health, 2013, 216, 333-340.	4.3	16
81	The IL-33/ST2 Axis Is Associated with Human Visceral Leishmaniasis and Suppresses Th1 Responses in the Livers of BALB/c Mice Infected with Leishmania donovani. MBio, 2013, 4, e00383-13.	4.1	50
82	VOC Contamination in Hospital, from Stationary Sampling of a Large Panel of Compounds, in View of Healthcare Workers and Patients Exposure Assessment. PLoS ONE, 2013, 8, e55535.	2.5	76
83	Impaired Functions of Macrophage from Cystic Fibrosis Patients: CD11b, TLR-5 Decrease and sCD14, Inflammatory Cytokines Increase. PLoS ONE, 2013, 8, e75667.	2.5	61
84	Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. Journal of Antimicrobial Chemotherapy, 2012, 67, 2731-2738.	3.0	41
85	Correlation between Environmental Relative Moldiness Index (ERMI) values in French dwellings and other measures of fungal contamination. Science of the Total Environment, 2012, 438, 319-324.	8.0	19
86	Invariant NKT Cells Drive Hepatic Cytokinic Microenvironment Favoring Efficient Granuloma Formation and Early Control of Leishmania donovani Infection. PLoS ONE, 2012, 7, e33413.	2.5	30
87	The placenta: a main role in congenital toxoplasmosis?. Trends in Parasitology, 2011, 27, 530-536.	3.3	65
88	High level of soluble HLA-G in amniotic fluid is correlated with congenital transmission of Toxoplasma gondii. Clinical Immunology, 2011, 138, 129-134.	3.2	29
89	Anti-Inflammatory Effect of Fluvastatin on IL-8 Production Induced by Pseudomonas aeruginosa and Aspergillus fumigatus Antigens in Cystic Fibrosis. PLoS ONE, 2011, 6, e22655.	2.5	21
90	Clinical Relevance of Placenta Examination for the Diagnosis of Congenital Toxoplasmosis. Pediatric Infectious Disease Journal, 2010, 29, 33-38.	2.0	64

#	Article	IF	Citations
91	Correlation of Parasite Load Determined by Quantitative PCR to Clinical Outcome in a Heart Transplant Patient with Disseminated Toxoplasmosis. Journal of Clinical Microbiology, 2010, 48, 2541-2545.	3.9	51
92	Immunostimulatory Properties of Dendritic Cells after Leishmania donovani Infection Using an In Vitro Model of Liver Microenvironment. PLoS Neglected Tropical Diseases, 2010, 4, e703.	3.0	10
93	Epidemiology of invasive aspergillosis and risk factors in non neutropaenic patients. Revue Des Maladies Respiratoires, 2010, 27, e34-e46.	1.7	25
94	Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006). Critical Care Medicine, 2009, 37, 1612-1618.	0.9	453
95	Near-Fatal Multiple Organ Dysfunction Syndrome Induced byPlasmodium malariae. Emerging Infectious Diseases, 2009, 15, 832-834.	4.3	16
96	Mycoses profondes et transplantation. Revue Francophone Des Laboratoires, 2008, 2008, 41-48.	0.0	1
97	Evaluation of a new mobile system for protecting immune-suppressed patients against airborne contamination. American Journal of Infection Control, 2007, 35, 460-466.	2.3	15
98	Recurrent American Cutaneous Leishmaniasis. Emerging Infectious Diseases, 2007, 13, 1436-1438.	4.3	21
99	Bacterial and Fungal Counts in Hospital Air: Comparative Yields for 4 Sieve Impactor Air Samplers With 2 Culture Media. Infection Control and Hospital Epidemiology, 2006, 27, 1405-1408.	1.8	30
100	Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis. Clinical and Experimental Immunology, 2006, 147, 061129014413003-???.	2.6	49
101	In Vitro and Ex Vivo Permissivity of Hepatocytes forLeishmania donovani. Journal of Eukaryotic Microbiology, 2005, 52, 489-491.	1.7	10
102	Experimental assessment of disinfection procedures for eradication of Aspergillus fumigatus in food. Blood, 2004, 104, 2000-2002.	1.4	18
103	Prospective Value of PCR Amplification and Sequencing for Diagnosis and Typing of Old World Leishmania Infections in an Area of Nonendemicity. Journal of Clinical Microbiology, 2003, 41, 1419-1422.	3.9	46
104	Prevention of Nosocomial Fungal Infection: The French Approach. Clinical Infectious Diseases, 2002, 35, 343-346.	5.8	36
105	Transient aspergillus antigenaemia: think of milk. Lancet, The, 2002, 359, 1251.	13.7	48
106	Experimental Pathogenicity of a Presumed Monoxenous Trypanosomatid Isolated from Humans in a Murine Model. Journal of Eukaryotic Microbiology, 2001, 48, 170-176.	1.7	21
107	Virulence of Leishmania infantum Is Expressed as a Clonal and Dominant Phenotype in Experimental Infections. Infection and Immunity, 2001, 69, 7365-7373.	2.2	38
108	Evidence for determining parasitic factors in addition to host genetics and immune status in the outcome of murine Leishmania infantum visceral leishmaniasis. Parasite Immunology, 2000, 22, 515-519.	1.5	16

#	Article	lF	CITATIONS
109	Fungal Contamination of Food in Hematology Units. Journal of Clinical Microbiology, 2000, 38, 4272-4273.	3.9	106
110	Experimental Evaluation of Second-Line Oral Treatments of Visceral Leishmaniasis Caused by Leishmania infantum. Antimicrobial Agents and Chemotherapy, 1999, 43, 172-174.	3.2	48